A review of malignancies observed during efalizumab (Raptiva®) clinical trials for plaque psoriasis

Background: Psoriasis is a chronic, incurable immune-mediated disease. Most therapies used for moderate to severe psoriasis are immunosuppressive. Agents that depress immune functio